July 17, 2019

(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on today’s announcement by the Administration to reduce prescription drug out-of-pocket costs for consumers:

“PCMA applauds the Administration for expanding preventive care benefits to include prescription drugs for patients with chronic conditions. There is no question that there is a prescription drug affordability problem. For patients in high-deductible plans, insulin products have become increasingly unaffordable.

Drug manufacturers alone set and raise prescription drug prices. On average, the price for insulin has nearly doubled in just five years, and very little generic or biosimilar competition exists to reduce prices.

The Administration’s guidance to allow consumers enrolled in high-deductible health care plans and health savings accounts the ability to obtain medications, such as insulin, without paying cost-sharing is an important step forward in the fight to lower drug costs.”